Lymphoproliferative Disorders D008232

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders

Description

Disorders characterized by proliferation of lymphoid tissue, general or unspecified.   MeSH

Subtype Terms (21)

Agammaglobulinemia
24 drugs (21 approved, 3 experimental)

Autoimmune Lymphoproliferative Syndrome
5 approved drugs

Castleman Disease
22 drugs (20 approved, 2 experimental)

Granuloma
38 drugs (29 approved, 9 experimental)

Heavy Chain Disease
 

Immunoblastic Lymphadenopathy
1 approved drug

Immunoglobulin Light-chain Amyloidosis
51 drugs (40 approved, 11 experimental)

Immunoproliferative Small Intestinal Disease
 

Infectious Mononucleosis
7 drugs (4 approved, 3 experimental)

Leukemia, Hairy Cell
87 drugs (61 approved, 26 experimental)

Leukemia, Lymphoid
135 drugs (80 approved, 55 experimental)

Lymphangiomyoma
1 approved drug

Lymphoma
934 drugs (373 approved, 561 experimental)

Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)

Marek Disease
 

Multiple Myeloma
836 drugs (294 approved, 542 experimental)

Plasmacytoma
84 drugs (59 approved, 25 experimental)

Sarcoidosis
53 drugs (40 approved, 13 experimental)

Sezary Syndrome
121 drugs (80 approved, 41 experimental)

Tumor Lysis Syndrome
4 approved drugs

Waldenstrom Macroglobulinemia
168 drugs (94 approved, 74 experimental)


Approved Indicated Drugs (1)


Organization Involved with Phase 4 Indications (3)

Organization Involved with Other Experimental Indications (4)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.